STAAR Surgical Company (STAA) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $24.45 (-3.15%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 15, 2026 | John Young | Canaccord Genuity | $22.00 | -10.0% |
| Dec 10, 2025 | Simran Kaur | Wells Fargo | $30.75 | +25.8% |
| Dec 9, 2025 | John Young | Canaccord Genuity | $30.75 | +25.8% |
| Oct 21, 2025 | John Young | Canaccord Genuity | $28.00 | +14.5% |
| Aug 7, 2025 | Thomas Stephan | Stifel Nicolaus | $28.00 | +14.5% |
| Jun 11, 2024 | Ryan Zimmerman | BTIG | $46.00 | +88.2% |
| Apr 9, 2024 | Raj Denhoy | Jefferies | $60.00 | +145.4% |
| Apr 8, 2024 | John Young | Canaccord Genuity | $46.00 | +88.2% |
| Apr 4, 2024 | Margaret Kaczor | William Blair | $45.03 | +84.2% |
| Jan 11, 2023 | Stephens Stephens | Stephens | $85.00 | +247.7% |
| Mar 23, 2022 | Michael Ciarmoli | Truist Financial | $58.00 | +137.3% |
Top Analysts Covering STAA
STAA vs Sector & Market
| Metric | STAA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.41 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +26.4% | +153002.0% | +21.5% |
| P/E Ratio | -16.45 | 3.49 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-02 | $285M | $310M | $327M | 8 |
| 2027-04-02 | $74M | $81M | $87M | 3 |
| 2027-07-02 | $82M | $89M | $97M | 3 |
| 2027-10-02 | $79M | $87M | $94M | 3 |
| 2028-01-02 | $69M | $75M | $81M | 2 |
| 2028-04-02 | $74M | $81M | $87M | 2 |
| 2028-07-02 | $82M | $89M | $96M | 2 |
| 2028-10-02 | $92M | $101M | $109M | 2 |
| 2029-01-02 | $76M | $83M | $89M | 4 |
| 2030-01-02 | $396M | $432M | $456M | 6 |
| 2031-01-02 | $449M | $489M | $517M | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-02 | $0.31 | $0.39 | $0.44 | 5 |
| 2027-04-02 | $0.15 | $0.17 | $0.19 | 1 |
| 2027-07-02 | $0.20 | $0.23 | $0.25 | 1 |
| 2027-10-02 | $0.17 | $0.20 | $0.22 | 1 |
| 2028-01-02 | $0.14 | $0.16 | $0.18 | 2 |
| 2028-04-02 | $0.11 | $0.13 | $0.14 | 2 |
| 2028-07-02 | $0.16 | $0.18 | $0.20 | 2 |
| 2028-10-02 | $0.16 | $0.18 | $0.20 | 2 |
| 2029-01-02 | $0.06 | $0.07 | $0.07 | 1 |
| 2030-01-02 | $1.13 | $1.27 | $1.36 | 2 |
| 2031-01-02 | $1.42 | $1.59 | $1.71 | 3 |
Frequently Asked Questions
What is the analyst consensus for STAA?
The consensus among 16 analysts covering STAAR Surgical Company (STAA) is Buy with an average price target of $30.89.
What is the highest price target for STAA?
The highest price target for STAA is $85.00, set by Stephens Stephens at Stephens on 2023-01-11.
What is the lowest price target for STAA?
The lowest price target for STAA is $22.00, set by John Young at Canaccord Genuity on 2026-01-15.
How many analysts cover STAA?
16 analysts have issued ratings for STAAR Surgical Company in the past 12 months.
Is STAA a buy or sell right now?
Based on 16 analyst ratings, STAA has a consensus rating of Buy (2.50/5) with a +26.4% upside to the consensus target of $30.89.
What are the earnings estimates for STAA?
Analysts estimate STAA will report EPS of $0.39 for the period ending 2027-01-02, with revenue estimated at $310M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.